Dr. Dan Estes is a General Partner on the Frazier Life Sciences team and focuses on company formation and investments in private biopharmaceutical companies. He has been a co-founder of seven companies, including Arcutis (NASDAQ: ARQT), Lengo Therapeutics and Sudo Biosciences, and currently serves on the board of directors of Inipharm, Hummingbird Bioscience, Radionetics Oncology, Hillstar Bio, and Iolyx Therapeutics. He previously served on the boards of Semnur Pharmaceuticals (acquired by Scilex), Arcutis (NASDAQ: ARQT), and Sierra Oncology (acquired by GSK), and led Frazier’s investment in Tarsus Pharmaceuticals (NASDAQ: TARS). He has also been involved with Frazier’s investments in Acerta Pharma BV (acquired by AstraZeneca), Tobira Therapeutics (acquired by Allergan), Ignyta (acquired by Roche), Iovance (NASDAQ: IOVA), Vaxcyte (NADAQ: PCVX), and PreCision Dermatology (acquired by Valeant).

Prior to joining Frazier, Dr. Estes was a management consultant with McKinsey & Company’s global pharmaceutical practice. He received his Ph.D. in Biomedical Engineering from the University of Michigan and holds a B.S. in Electrical Engineering from Stanford University.